NEW YORK (GenomeWeb) – Biocartis said today that its tissue-based Idylla NRAS-BRAF mutation test has been CE marked and can now be sold throughout the European Economic Area.
According to the company, the combination of the new NRAS-BRAF mutation test with its existing KRAS assay means that it can offer customers a complete solution for clinical testing of metastatic colorectal cancers, as recommended by the most recent professional guidelines.